BioArctic AB (publ)

Research BioArctic AB (publ) (BIOA-B) on Bullrun: valuation model: 54.6% overvalued, market cap SEK 27.86B, P/E 131.4, dividend yield 0.6%. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerBIOA-B
• ExchangeST
• CountrySweden
• SectorHealthcare
• IndustryBiotechnology
• CurrencySEK
• Valuation signal54.6% overvalued
• Market capSEK 27.86B
• P/E131.4
• Dividend yield0.6%
• Financial periodFY2024
• RevenueSEK 257.35M
• Revenue growth-58.2%
• Net income-SEK 228.52M
• Gross margin89.5%

Valuation Snapshot

Bullrun's latest valuation model marks BioArctic AB (publ) as 54.6% overvalued; latest market cap is SEK 27.86B; P/E is 131.4; dividend yield is 0.6%.

About BioArctic AB (publ)

BioArctic AB (publ) develops biological drugs for patients with central nervous system disorders in Sweden. It engages in the research and development of biological drugs, such as antibodies that address high unmet medical needs. The company's therapeutic areas encompass neurodegenerative disorders, such as Alzheimer's disease, Parkinson's disease, and other ALS diseases. In addition, it offers Lecanemab for intravenous treatment.

Frequently asked questions

Is BioArctic AB (publ) overvalued or undervalued?

Bullrun's valuation model currently marks BioArctic AB (publ) as 54.6% overvalued.

What is BioArctic AB (publ)'s market cap?

BioArctic AB (publ)'s market capitalization is SEK 27.86B.

What is BioArctic AB (publ)'s P/E ratio?

BioArctic AB (publ)'s price-to-earnings (P/E) ratio is 131.4.

Does BioArctic AB (publ) pay a dividend?

BioArctic AB (publ) has a dividend yield of 0.6%.

What does BioArctic AB (publ) do?

BioArctic AB (publ) develops biological drugs for patients with central nervous system disorders in Sweden. It engages in the research and development of biological drugs, such as antibodies that address high unmet medical needs.